Last reviewed 2026-04-20 · How we verify

Ethebenecid (ETEBENECID)

Phase 2 active Small molecule

Ethebenecid (generic name: ETEBENECID) is a etebenecid drug. It is currently in Phase 2 development.

Ethebenecid is thought to work by inhibiting the transport of certain substances across cell membranes.

Ethebenecid is a small molecule drug in the etebenecid class, but specific details about its development, commercial status, and approved indications are not available. As a result, there is limited information about its target, pharmacokinetics, and safety profile. Further research is needed to understand the clinical utility and potential risks associated with etebenecid. The exact mechanism of action and approved uses of etebenecid are currently unknown. It is essential to consult reliable sources for accurate information about this drug.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ETEBENECID
Drug class	etebenecid
Modality	Small molecule
Therapeutic area	Nephrology
Phase	Phase 2

Mechanism of action

Imagine your cells have special doors that let certain things in and out. Ethebenecid blocks these doors, preventing certain substances from entering or leaving the cell. This can affect how the cell works and responds to its environment.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Ethebenecid CI brief — competitive landscape report
Ethebenecid updates RSS · CI watch RSS

Frequently asked questions about Ethebenecid

What is Ethebenecid?

Ethebenecid (ETEBENECID) is a etebenecid drug.

How does Ethebenecid work?

Ethebenecid is thought to work by inhibiting the transport of certain substances across cell membranes.

What is the generic name of Ethebenecid?

ETEBENECID is the generic (nonproprietary) name of Ethebenecid.

What drug class is Ethebenecid in?

Ethebenecid belongs to the etebenecid class. See all etebenecid drugs at /class/etebenecid.

What development phase is Ethebenecid in?

Ethebenecid is in Phase 2.

Drug class: All etebenecid drugs
Therapeutic area: All drugs in Nephrology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing